Search Results
Search for other papers by E Baudin in
Google Scholar
PubMed
Search for other papers by J Capdevila in
Google Scholar
PubMed
Search for other papers by D Hörsch in
Google Scholar
PubMed
Search for other papers by S Singh in
Google Scholar
PubMed
Search for other papers by M E Caplin in
Google Scholar
PubMed
Search for other papers by E M Wolin in
Google Scholar
PubMed
Search for other papers by W Buikhuisen in
Google Scholar
PubMed
Search for other papers by M Raderer in
Google Scholar
PubMed
Search for other papers by E Dansin in
Google Scholar
PubMed
Search for other papers by C Grohe in
Google Scholar
PubMed
Search for other papers by D Ferone in
Google Scholar
PubMed
Search for other papers by A Houchard in
Google Scholar
PubMed
Search for other papers by X-M Truong-Thanh in
Google Scholar
PubMed
Search for other papers by D Reidy-Lagunes in
Google Scholar
PubMed
Search for other papers by the SPINET Study Group in
Google Scholar
PubMed
Prospective data are lacking on early somatostatin analog (SSA) therapy in bronchopulmonary neuroendocrine tumors (BP-NETs; typical carcinoids and atypical carcinoids (TCs and ACs)). SPINET (EudraCT: 2015-004992-62; NCT02683941) was a phase III, double-blind study of lanreotide autogel/depot (LAN; 120 mg every 28 days) plus best supportive care (BSC) vs placebo plus BSC, with an optional open-label treatment phase (LAN plus BSC). Patients had metastatic/unresectable, somatostatin receptor (SSTR)-positive TCs or ACs. Recruitment was stopped early owing to slow accrual; eligible patients from the double-blind phase transitioned to open-label LAN. The adapted primary endpoint was progression-free survival (PFS) during either phase for patients receiving LAN. Seventy-seven patients were randomized (LAN, n = 51 (TCs, n = 29; ACs, n = 22); placebo, n = 26 (TCs, n = 16; ACs, n = 10)). Median (95% CI) PFS during double-blind and open-label phases in patients receiving LAN was 16.6 (11.3; 21.9) months overall (primary endpoint), 21.9 (12.8, not calculable (NC)) months in TCs, and 13.8 (5.4; 16.6) months in ACs. During double-blind treatment, median (95% CI) PFS was 16.6 (11.3; 21.9) months for LAN vs 13.6 (8.3; NC) months for placebo (not significant); corresponding values were 21.9 (13.8; NC) and 13.9 (13.4; NC) months, respectively, in TCs and 13.8 (5.4; 16.6) and 11.0 (2.8; 16.9) months, respectively, in ACs. Patients’ quality of life did not deteriorate and LAN was well tolerated. Although recruitment stopped early and the predefined sample size was not met, SPINET is the largest prospective study to date of SSA therapy in SSTR-positive TCs and ACs and suggests clinical benefit in TCs.
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Search for other papers by Mariella Minoia in
Google Scholar
PubMed
Search for other papers by Chiara Martini in
Google Scholar
PubMed
Search for other papers by Federico Tagliati in
Google Scholar
PubMed
Search for other papers by Maria Rosaria Ambrosio in
Google Scholar
PubMed
Search for other papers by Marco Schiavon in
Google Scholar
PubMed
Search for other papers by Mattia Buratto in
Google Scholar
PubMed
Search for other papers by Fiorella Calabrese in
Google Scholar
PubMed
Search for other papers by Erica Gentilin in
Google Scholar
PubMed
Search for other papers by Giorgio Cavallesco in
Google Scholar
PubMed
Search for other papers by Lisa Berdondini in
Google Scholar
PubMed
Search for other papers by Federico Rea in
Google Scholar
PubMed
Search for other papers by Ettore C degli Uberti in
Google Scholar
PubMed
in a neuro-endocrine tumour cell line . Neuroendocrinology 87 168 – 181 . Gustafsson BI Kidd M Chan A Malfertheiner MV Modlin IM 2008 Bronchopulmonary neuroendocrine tumors . Cancer 113 5 – 21 . Korbonits M Bustin SA Kojima
Division of Pulmonary and Critical Care Medicine, Asante Health System, Medford, Oregon, USA
Search for other papers by Bilal F Samhouri in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Chi Wan Koo in
Google Scholar
PubMed
Department of Respiratory Medicine, St Vincent’s University Hospital, Elm Park, Dublin, Ireland
Search for other papers by Cormac McCarthy in
Google Scholar
PubMed
Search for other papers by Eunhee S Yi in
Google Scholar
PubMed
Search for other papers by Charles F Thomas in
Google Scholar
PubMed
Search for other papers by Jay H Ryu in
Google Scholar
PubMed
Rydel M Robek A Pierzchała S Malczewska M , 2021 Prospective evaluation of the NETest as a liquid biopsy for gastroenteropancreatic and bronchopulmonary neuroendocrine tumors: an Enets center of excellence experience . Neuroendocrinology 111
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Search for other papers by Giuseppe Fanciulli in
Google Scholar
PubMed
Search for other papers by Pasqualino Malandrino in
Google Scholar
PubMed
Search for other papers by Valeria Ramundo in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by on behalf of NIKE Group in
Google Scholar
PubMed
bronchopulmonary neuroendocrine tumors . Experimental and Therapeutic Medicine 2 787 – 792 . ( doi:10.3892/etm.2011.291 ). van Asselt SJ Oosting SF Brouwers AH Bongaerts AH de Jong JR Lub-de Hooge MN Oude Munnink TH Fiebrich HB Sluiter WJ
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Search for other papers by Mark Kidd in
Google Scholar
PubMed
Search for other papers by Leah Meuter in
Google Scholar
PubMed
Search for other papers by Irvin M Modlin in
Google Scholar
PubMed
bronchopulmonary neuroendocrine tumors (BPNET) and as a tool to evaluate surgical resection and disease progression . European Journal of Cardio-Thoracic Surgery 53 631 – 639 . ( https://doi.org/10.1093/ejcts/ezx386 ) Fishbein L Leshchiner I Walter V
Search for other papers by Judith A Gilbert in
Google Scholar
PubMed
Search for other papers by Laura J Adhikari in
Google Scholar
PubMed
Search for other papers by Ricardo V Lloyd in
Google Scholar
PubMed
Search for other papers by Joseph Rubin in
Google Scholar
PubMed
Search for other papers by Paul Haluska in
Google Scholar
PubMed
Search for other papers by Joan M Carboni in
Google Scholar
PubMed
Search for other papers by Marco M Gottardis in
Google Scholar
PubMed
Search for other papers by Matthew M Ames in
Google Scholar
PubMed
IGF1R and Hsp90 for development of novel anticancer drugs for, at a minimum, bronchopulmonary neuroendocrine tumors. Supplementary data This is linked to the online version of the paper at http://dx.doi.org/10.1677/ERC-09-0318 . Declaration of
Member of the German Cancer Consortium (DKTK), Germany
Search for other papers by Atsuko Kasajima in
Google Scholar
PubMed
Search for other papers by Günter Klöppel in
Google Scholar
PubMed
patients with typical bronchial carcinoid tumors . Journal of Clinical Endocrinology and Metabolism 85 3425 – 3430 . Gustafsson BI Kidd M Chan A Malfertheiner MV Modlin IM 2008 Bronchopulmonary neuroendocrine tumors . Cancer 113
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Elke Tatjana Aristizabal Prada in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Vera Heinzle in
Google Scholar
PubMed
Institute of Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Thomas Knösel in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Svenja Nölting in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Gerald Spöttl in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Julian Maurer in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Christine Spitzweg in
Google Scholar
PubMed
Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Martin Angele in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Nina Schmidt in
Google Scholar
PubMed
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland
Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
Search for other papers by Günter K Stalla in
Google Scholar
PubMed
Search for other papers by Rainer Blaser in
Google Scholar
PubMed
Search for other papers by Klaus A Kuhn in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Christoph J Auernhammer in
Google Scholar
PubMed
Vlotides G Spottl G Maurer J Goke B Auernhammer CJ 2014 Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells . World Journal of Gastroenterology 20 10038 – 10049